Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Explore this paper's citation graph
Summary
The roles of VEGF and ANG2 are outlined, and ways that antiangiogenic agents can be combined with immune-checkpoint inhibitors to potentially improve patient outcomes are suggested, and avenues of future research are highlighted.
- Type
- review
- Published
- 2018-03-06
- Cited by
- 1,784
- References
- 196
- Access
- Open access
- OpenAlex
- https://openalex.org/W2791328450
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4901671
Keywords
Immunotherapy, Immune system, Tumor microenvironment, Cancer immunotherapy, Medicine
References
- Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases.
- Expression of angiopoietin-2 is correlated with vascularization and tumor size in human colorectal adenocarcinoma.
- Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients.
- Endothelial cell‐derived angiopoietin‐2 is a therapeutic target in treatment‐naive and bevacizumab‐resistant glioblastoma
- Combining Radiation Therapy with Immune Checkpoint Blockade for Central Nervous System Malignancies
- Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
- CXCR4 inhibition in tumor microenvironment facilitates anti-PD-1 immunotherapy in sorafenib-treated HCC in mice
- Expression of Tie-2 by Human Monocytes and Their Responses to Angiopoietin-21
- Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function.
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti‐tumour effect in vivo
- Effects of Angiopoietin-2-Blocking Antibody on Endothelial Cell–Cell Junctions and Lung Metastasis
- Angiopoietin-1 protects the adult vasculature against plasma leakage
- Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
- Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels
- Combined therapy of local and metastatic 4T1 breast tumor in mice using SU6668, an inhibitor of angiogenic receptor tyrosine kinases, and the immunostimulator B7.2-IgG fusion protein.
- Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients
- Combining two strategies to improve perfusion and drug delivery in solid tumors
- VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2
- Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy
- The brain tumor microenvironment
Cited by
- Reengineering the physical microenvironment of tumors to improve drug delivery and efficacy: From math modeling to bench to bedside
- Current state of immunotherapy for glioblastoma
- Consensus guidelines for the use and interpretation of angiogenesis assays
- Redefining mesothelioma types as a continuum uncovers the immune and vascular systems as key players in the diagnosis and prognosis of this disease
- The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer
- Umbilical Cord Blood–Derived Natural Killer Cells Combined with Bevacizumab for Colorectal Cancer Treatment
- Immunotherapy-based combinations: an update
- Molecular therapies and precision medicine for hepatocellular carcinoma
- Photodynamic Therapy Based on Nanoscale Metal-Organic Frameworks: From Material Design to Cancer Nanotherapeutics.
- A Homing System Targets Therapeutic T-cells to Brain Cancer
- The Warburg Effect in Endothelial Cells and its Potential as an Anti-angiogenic Target in Cancer
- Iron addiction with ferroptosis‐resistance in asbestos‐induced mesothelial carcinogenesis: Toward the era of mesothelioma prevention
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy
- Role of the immunosuppressive microenvironment in immunotherapy
- A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma (HCC)
- Harnessing the immune system in glioblastoma
- Non-destructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy
- Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth.
- Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature.
Related papers
- Crucial Roles of Effectors in Interactions between Horticultural Crops and Pathogens
- Prediction of effector proteins and their implications in pathogenicity of phytopathogenic filamentous fungi: A review.
- Remote homology clustering identifies lowly conserved families of effector proteins in plant-pathogenic fungi
- The vasohibin family: a novel family for angiogenesis regulation.
- The vasohibin family: Novel regulators of angiogenesis.
- "Order from disordered": Potential role of intrinsically disordered regions in phytopathogenic oomycete intracellular effector proteins.
- Nanoparticle-Mediated Remodeling of the Tumor Microenvironment to Enhance Immunotherapy.
- Multifunctional Nanoparticles Boost Cancer Immunotherapy Based on Modulating the Immunosuppressive Tumor Microenvironment.